SCHEMBL22116293

SCHEMBL22116293

O=C1CN(c2cccc(S(=O)(=O)NC(=O)C3CC3)n2)CCN1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 3/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ PIM1 P11309 3/20 0.38
▸ PIM3 Q86V86 1/20 0.38
▸ PIM2 Q9P1W9 1/20 0.38
▸ CCNT1 O60563 1/20 0.37
▸ CDK4 P11802 1/20 0.37
▸ CCND1 P24385 1/20 0.37
▸ CCND3 P30281 1/20 0.37
▸ CDK9 P50750 1/20 0.37
▸ CDK6 Q00534 1/20 0.37
▸ HPGDS O60760 1/20 0.36
▸ STS P08842 1/20 0.34
▸ CYP1A2 P05177 1/20 0.34
▸ CYP3A4 P08684 1/20 0.34
▸ CYP2D6 P10635 1/20 0.34
▸ CYP2C9 P11712 1/20 0.34
▸ CYP2C19 P33261 1/20 0.34
▸ HPGD P15428 1/20 0.34
▸ OPRM1 P35372 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22116413 0.78 HPGD (0.39) STSCYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL22116332 0.78 HSD11B1 (0.44) STSHPGDTSHRAGTR1AGTR2
SCHEMBL22116414 0.78 ABL1 (0.43) JAK1STSCYP1A2CYP3A4CYP2D6
SCHEMBL30611688 0.78 ABL1 (0.43) JAK1STSCYP1A2CYP3A4CYP2D6
SCHEMBL30611680 0.78 ABL1 (0.43) JAK1STSCYP1A2CYP3A4CYP2D6
SCHEMBL22116366 0.78 ABL1 (0.43) JAK1STSCYP1A2CYP3A4CYP2D6
SCHEMBL30611670 0.77 ACACB (0.44) STSHPGDTSHR
SCHEMBL22116386 0.77 ACACB (0.44) STSHPGDTSHR
SCHEMBL22116307 0.76 KIF18A (0.42) JAK2JAK1STSCYP1A2CYP3A4
SCHEMBL30611793 0.76 KIF18A (0.42) JAK2JAK1STSCYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3897832-A1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE Novartis AG (CH) 2021-10-27 — — EP claimed
WO-2020128768-A1 N-(PYRIDIN-2-YLSULFONYL)CYCLOPROPANECARBOXAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF A CFTR MEDIATED DISEASE NOVARTIS AG (CH) 2020-06-25 — — WO claimed
Send feedback